Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 60 of 6351
-
New hope for hepatitis d: libevitug enters final testing phase
Disease control Recruiting nowThis is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Phase 3 • Sponsor: Huahui Health • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take on lupus nephritis
Disease control By invitation onlySystemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients. Currently, cell-based therapy has emerged as an innovative treatment approach f…
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot aims to slash stroke risk by crushing cholesterol
Disease control Not yet recruitingThe Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C …
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Two-Pronged gene therapy takes on deadly brain tumors
Disease control Recruiting nowThe goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma. TGX-007 is a gene therapy drug delivered by a…
Phase 1/2 • Sponsor: Trogenix ltd • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Gene-Editing shot aims to fix rare lung and liver disease
Disease control Recruiting nowThis is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver dis…
Phase 1/2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for advanced breast cancer: experimental combo enters phase 3 trial
Disease control Recruiting nowThis trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast c…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New chikungunya vaccine trial aims to protect millions
Vaccine Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Phase 2/3 • Sponsor: Bharat Biotech International Limited • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC
-
Nano-ink gel could replace repeated skull surgeries for kids with rare genetic disorders
Disease control Recruiting nowSyndromic craniosynostoses (SCS) are rare genetic disorders defined by premature cranial suture fusion, resulting in abnormal craniofacial development and constrained brain growth. These conditions, including Muenke, Saethre-Chotzen, Crouzon, Apert, Pfeiffer and craniofrontonasal…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can a Pre-Surgery drug combo boost bile duct cancer survival?
Disease control Recruiting nowExtrahepatic cholangiocarcinoma (eCCA) is a rare and aggressive cancer with poor prognosis. ECCA can be further subcategorised in perihilar and distal cholangiocarcinoma (pCCA and dCCA). Surgical resection is the only potential cure, but only one-third of patients are eligible. E…
Phase 2/3 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for stomach cancer: targeted drug combo enters final testing
Disease control Recruiting nowThis study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients w…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to outsmart aggressive colon cancer
Disease control Recruiting nowThis is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant …
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could an HIV drug extend life in Creutzfeldt-Jakob disease?
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of efavirenz in patients with Creutzfeldt-Jakob disease (CJD). A total of 246 eligible participants will be enrolled across 21 study cen…
Phase 3 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Hope for Late-Stroke patients: clot removal may boost recovery even after 24 hours
Disease control Recruiting nowSELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving bette…
Sponsor: Amrou Sarraj • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Blood test may spot prostate cancer without a needle
Diagnosis Recruiting nowThis is a single-center, prospective diagnostic accuracy trial conducted at Renji Hospital, Shanghai Jiao Tong University School of Medicine, led by a team of urology and molecular medicine researchers. A total of 500 male participants aged 18 years or older who meet clinical ind…
Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone.…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New pill combo aims to fight advanced kidney cancer
Disease control Recruiting nowResearchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted pill plus chemotherapy in Late-Stage trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could caffeine help save newborn brains? major trial launches
Disease control Recruiting nowCHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an u…
Phase 3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
A new strategy to prevent cervical cancer: community follow-up for HPV shots
Prevention OngoingThe goal of this trial is to learn if a community health worker (CHW) follow-up program can improve HPV vaccination coverage among adolescent girls in Mali and Côte d'Ivoire. The main questions it aims to answer are: Does the CHW follow-up program increase the number of girls wh…
Sponsor: Muso Health • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC